skip to main content
UK Health Security Agency

LDS 73/LW1

LDS 73/LW1

Catalogue No.

96050401

Cell Line Name

LDS 73/LW1

Cell Line Description

The hybridoma cell line LDS 73/LW1 was produced by fusing NS0 myeloma cells with spleen cells from an MF1 x BALB/c mouse immunised with rat glutathione S-transferase subunit YC2. The cell line, also known as LW1, secretes antibodies that distinguish between subunit YC2 and YC1.

General Info

Fusion Species

Mouse x Mouse Hybridoma

Target (Reactivity)

Anti-glutathione S-transferase subunit YC2

Release Conditions

Restricted - commercial organisations are required to complete the 'Cell Line Release Authorisation for Research Use in Commercial Organisations' release conditions form in the supporting documents section.

Characteristics

Myeloma

NS-0

Immunogen

Rat glutathione S-transferase subunit YC2

Immunological Donor

(MF1 x BALB/c) F mouse spleen

Antibody Isotype

IgG2a

Morphology

Spherical

Tissue of Origin

Hybrid

Culture Conditions

Cell Type

Hybridoma

Subculture Routine

Maintain cultures between 3-9 x 100,000 cells/ml; 5% CO₂; 37°C. When recovering hybridoma cultures from frozen it is not unusual for growth to be slower than expected initially and there may be an observed decrease in viability. Establishment of an actively proliferating culture may take up to 2 weeks. On resuscitation a centrifugation step to remove the cryoprotectant is essential. Rapidly thaw the frozen ampoule in a water bath at 37°C for 1-2 minutes. Transfer the contents to a centrifuge tube and slowly add 5-10ml of prewarmed growth media+. Remove a sample for counting. Centrifuge at 100 x g for 2-3 minutes to pellet cells and seed at a relatively high density of 5-7 x 10µ cells/ml. Place culture flask flat and observe regularly until viable proliferating cells are seen. Often hybridoma cultures may benefit from being resuspended with media supplemented with 20% FBS in the early critical stage of culture establishment immediately post resuscitation. Once the culture is established in culture the FBS can be reduced to 10%.

Culture Medium

RPMI 1640 or DMEM + 2mM glutamine + 10% Foetal Bovine Serum (FBS)

Growth Mode

Suspension

Additional Info

Depositor

Dr G E Neal, MRC Toxicology Unit, University of Leicester

Country of Origin

United Kingdom

Applications

Immunohistochemistry, Western blotting, ELISA assays

Hazard Group (ACDP)

2

References

References

None Specifed By Depositor

Available Formats

  • Frozen

If use of this culture results in a scientific publication, it should be cited in the publication as: LDS 73/LW1 (ECACC 96050401)

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.